Acute Renal Failure Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2026-2036

 Market Overview:

The acute renal failure market reached a value of USD 40,427.5 Million across the top 7 markets (US, EU4, UK, and Japan) in 2025. Looking forward, IMARC Group expects the top 7 major markets to reach USD 60,321.7 Million by 2036, exhibiting a growth rate (CAGR) of 3.59% during 2026-2036.

The acute renal failure market has been comprehensively analyzed in IMARC's new report titled "Acute Renal Failure Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2026-2036". Acute renal failure is a medical condition characterized by a sudden and rapid decline in kidney function. In this disease, the kidneys are unable to perform their function properly, leading to a buildup of waste products and harmful fluids in the body. The indications of the ailment include decreased or no urine output, swelling in the legs, ankles, or face, fluid retention, fatigue, weakness, altered mental status, lethargy, nausea, vomiting, loss of appetite, confusion, difficulty concentrating, shortness of breath, chest pain or pressure, irregular heartbeat, abdominal discomfort, etc. The diagnosis of acute renal failure typically involves a combination of medical history evaluation, physical examination, and laboratory tests. The healthcare provider will initially assess the levels of blood urea nitrogen (BUN) and creatinine in the blood. In some cases, various imaging studies, such as ultrasounds, computed tomography scans, magnetic resonance imaging, etc., are also utilized to evaluate the structure and condition of the kidneys and urinary tract. These tests can help in identifying any obstructions or abnormalities in patients and rule out other possible diseases. 

To get more information on this market, Request Sample

The increasing incidences of severe dehydration, low blood pressure, infections, etc., which lead to reduced blood flow to the kidneys, are primarily driving the acute renal failure market. In addition to this, the rising cases of blockages in the urinary tract, like kidney stones or an enlarged prostate, that can obstruct urine flow and cause renal damage, are also creating a positive outlook for the market. Moreover, the widespread adoption of effective drugs, including diuretics and angiotensin-converting enzyme inhibitors, to control blood pressure and relieve fluid overload in the body, is further bolstering the market growth. Apart from this, the escalating application of continuous renal replacement therapy, since it offers continuous clearance of solutes and toxins from the blood, thereby allowing better control of uremia and metabolic disturbances associated with the ailment, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of erythropoiesis-stimulating agents, which effectively enhance red blood cell production and help in alleviating disease symptoms, is expected to drive the acute renal failure market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the acute renal failure market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for acute renal failure and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the acute renal failure market in any manner.

Time Period of the Study

• Base Year: 2025
• Historical Period: 2020-2025
• Market Forecast: 2026-2036

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the acute renal failure market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the acute renal failure market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current acute renal failure marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the acute renal failure market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2025 and how are they expected to perform till 2036?
• What was the country-wise size of the acute renal failure across the seven major markets in 2025 and what will it look like in 2036?
• What is the growth rate of the acute renal failure across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of incident cases (2020-2036) of acute renal failure across the seven major markets?
• What is the number of incident cases (2020-2036) of acute renal failure by age across the seven major markets?
• What is the number of incident cases (2020-2036) of acute renal failure by gender across the seven major markets?
• What is the number of incident cases (2020-2036) of acute renal failure by type across the seven major markets?
• How many patients are diagnosed (2020-2036) with acute renal failure across the seven major markets?
• What is the size of the acute renal failure patient pool (2020-2025) across the seven major markets?
• What would be the forecasted patient pool (2026-2036) across the seven major markets?
• What are the key factors driving the epidemiological trend acute renal failure of?
• What will be the growth rate of patients across the seven major markets?

Acute Renal Failure: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for acute renal failure drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the acute renal failure market?
• What are the key regulatory events related to the acute renal failure market?
• What is the structure of clinical trial landscape by status related to the acute renal failure market?
• What is the structure of clinical trial landscape by phase related to the acute renal failure market?
• What is the structure of clinical trial landscape by route of administration related to the acute renal failure market?